According to the Chinese Antibody Announcement, SM17 achieved positive results in a phase 1B clinical trial for the treatment of moderate to severe specific dermatitis in China. More than 90% of patients achieved an NRS-4 response, more than 70% achieved an EASI75 response, and more than 40% achieved an IGA0/1 response. There were no serious adverse events SAE, and there were no drug-related adverse events of grade 3 or above. SM17 performed better than IL-4 receptor inhibitor monoclonal antibody, JAK inhibitor, and IL-31 receptor inhibitor monoclonal antibody in terms of pruritus improvement indicator-NRS-4 ratio.

According to the Chinese Antibody Announcement, SM17 achieved positive results in a phase 1B clinical trial for the treatment of moderate to severe specific dermatitis in China. More than 90% of patients achieved an NRS-4 response, more than 70% achieved an EASI75 response, and more than 40% achieved an IGA0/1 response. There were no serious adverse events SAE, and there were no drug-related adverse events of grade 3 or above. SM17 performed better than IL-4 receptor inhibitor monoclonal antibody, JAK inhibitor, and IL-31 receptor inhibitor monoclonal antibody in terms of pruritus improvement indicator-NRS-4 ratio.